Biotech News

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid (PYPD)PolyPid2026-03-31 12:30 ESTFDA / regulatory

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative

Related news

PYPDPolyPid2025-12-03 13:30 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks. D-PLEX100 D-PLEX100 delivers doxycycline locally after...

Recent company news

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PYPDPolyPid2026-07-29 12:30 EST

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PYPDPolyPid2026-07-21 11:30 EST

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-05-20 12:30 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

Stock data

Close: 4.81 USD
Market cap: 93.38M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States